Description of the low-affinity interaction between nociceptin and the second extracellular loop of its receptor by fluorescence and NMR spectroscopies

Journal of Peptide Science

Volumn 14, Issue 11, 2008, Pages 1183-1194

  Vincent, Bruno ^a,b   Mouledous, Lionel ^a,b   Bes, Brice ^a,b   Mazarguil, Honore ^a,b   Meunier, Jean Claude ^a,b   Milon, Alain ^a,b   Demange, Pascal ^a,b  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Dynorphin; Extracellular loop; GPCR; Membrane receptors; Neuropeptides; NMR spectroscopy; Nociceptin; Opioid receptors

Indexed keywords

DYNORPHIN; NOCICEPTIN; NOCICEPTIN RECEPTOR; TRYPTOPHAN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DISSOCIATION CONSTANT; FLUORESCENCE SPECTROSCOPY; HUMAN; HYDROPHOBICITY; LIGAND BINDING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; RECEPTOR BINDING; STEREOCHEMISTRY;

CELL MEMBRANE; DYNORPHINS; HUMANS; IONS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, FLUORESCENCE; NEUROPEPTIDES; OPIOID PEPTIDES; PEPTIDES; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, OPIOID; SPECTROMETRY, FLUORESCENCE;

EID: 57849140607     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.1057     Document Type: Article

References (51)

1. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, Prinssen EP. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets. 2007; 8: 117-135.
2. Meunier J-C. The potential therapeutic value of nociceptin receptor agonists and antagonists. Expert Opin. Ther. Pat. 2000; 10: 371-388.
3. Meunier J, Mouledous L, Topham CM. The nociceptin (ORL1) receptor: molecular cloning and functional architecture. Peptides 2000; 21: 893-900.
4. Philip AE, Poupaert JH, McCurdy CR. Opioid receptor-like 1 (ORL1) molecular 'road map' to understanding ligand interaction and selectivity. Curr. Top. Med. Chem. 2005; 5: 325-340.
5. Topham CM, Mouledous L, Poda G, Maigret B, Meunier JC. Molecular modelling of the ORL1 receptor and its complex with nociceptin. Protein Eng. 1998; 11: 1163-1179.
6. Metzger TG, Ferguson DM. On the role of extracellular loops of opioid receptors in conferring ligand selectivity. FEBS Lett. 1995; 375: 1-4.
7. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000; 289: 739-745.
8. Rasmussen SGF, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VRP, Sanishvili R, Fischetti RF, Schertler GFX, Weis WI, Kobilka BK. Crystal structure of the human beta(2) adrenergic G-protein-coupled receptor. Nature 2007; 450: 383-387.
9. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SGF, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, Stevens RC. High-resolution crystal structure of an engineered human beta(2)-adrenergic G protein-coupled receptor. Science 2007; 318: 1258-1265.
10. Sarramegna V, Talmont R, Demange P, Milon A. Heterologous expression of G-protein-coupled receptors: comparison of expression systems from the standpoint of large-scale production and purification. Cell. Mol. Life Sci. 2003; 60: 1529-1546.
11. Yeagle PL, Albert AD. G-protein coupled receptor structure. Biochim. Biophys. Acta 2007; 1768: 530-537.
12. Katragadda M, Alderfer JL, Yeagle PL. Solution structure of the loops of bacteriorhodopsin closely resembles the crystal structure. Biochim. Biophys. Acta 2000; 1466: 1-6.
13. Ruan KH, So SP, Wu J, Li D, Huang A, Kung J. Solution structure of the second extracellular loop of human thromboxane A2 receptor. Biochemistry 2001; 40: 275-280.
14. Zhang L, DeHaven RN, Goodman M. NMR and modeling studies of a synthetic extracellular loop II of the kappa opioid receptor in a DPC micelle. Biochemistry 2002; 41: 61-68.
15. Petry R, Craik D, Haaima G, Fromme B, Klump H, Kiefer W, Palm D, Millar R. Secondary structure of the third extracellular loop responsible for ligand selectivity of a mammalian gonadotropin-releasing hormone receptor. J. Med. Chem. 2002; 45: 1026-1034.
16. Nicastro G, Peri F, Franzoni L, de Chiara C, Sartor G, Spisni A. Conformational features of a synthetic model of the first extracellular loop of the angiotensin II AT1A receptor. J. Pept. Sci. 2003; 9: 229-243.
17. Ruan KH, Wu J, So SP, Jenkins LA. Evidence of the residues involved in ligand recognition in the second extracellular loop of the prostacyclin receptor characterized by high resolution 2D NMR techniques. Arch. Biochem. Biophys. 2003; 418: 25-33.
18. Ulfers AL, Piserchio A, Mierke DF. Extracellular domains of the neurokinin-1 receptor: structural characterization and interactions with substance P. Biopolymers 2002; 66: 339-349.
19. Giragossian C, Mierke DF. Determination of ligand-receptor interactions of cholecystokinin by nuclear magnetic resonance. Life Sci. 2003; 73: 705-713.
20. Fadhil I, Schmidt R, Walpole C, Carpenter KA. Exploring deltorphin II binding to the third extracellular loop of the delta-opioid receptor. J. Biol. Chem. 2004; 279: 21069-21077.
21. Pham TCT, Kriwacki RW, Parrill AL. Peptide design and structural characterization of a GPCR loop mimetic. Biopolymers 2007; 86: 298-310.
22. Ye JP, Kohli LL, Stone MJ. Characterization of binding between the chemokine eotaxin and peptides derived from the chemokine receptor CCR3. J. Biol. Chem. 2000; 275: 27250-27257.
23. So SP, Wu JX, Huang GX, Huang AM, Li DW, Ruan KH. Identification of residues important for ligand binding of thromboxane A(2) receptor in the second extracellular loop using the NMR experiment-guided mutagenesis approach. J. Biol. Chem. 2003; 278: 10922-10927.
24. Amodeo P, Guerrini R, Picone D, Salvadori S, Spadaccini R, Tancredi T, Temussi PA. Solution structure of nociceptin peptides. J. Pept. Sci. 2002; 8: 497-509.
25. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, Butour JL, Guillemot JC, Ferrara P, Monsarrat B, Mazarguil H, Vassart G, Parmentier M, Constentin J. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor [see comments]. Nature 1995; 377: 532-535.
26. Mollereau C, Mouledous L, Lapalu S, Cambois G, Moisand C, Butour JL, Meunier JC. Distinct mechanisms for activation of the opioid receptor-like 1 and kappa-opioid receptors by nociceptin and dynorphin A. Mol. Pharmacol. 1999; 55: 324-331.
27. Lapalu S, Moisand C, Mazarguil H, Cambois G, Mollereau C, Meunier JC. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett. 1997; 417: 333-336.
28. Butour JL, Moisand C, Mazarguil H, Mollereau C, Meunier JC. Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids. Eur. J. Pharmacol. 1997; 321: 97-103.
29. Chavkin C, Goldstein A. Specific receptor for the opioid peptide dynorphin: structure-activity relationships. Proc. Natl. Acad. Sci. U.S.A. 1981; 78: 6543-6547.
30. Mansour A, Hoversten MT, Taylor LP, Watson SJ, Akil H. The cloned mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide recognition cores. Brain Res. 1995; 700: 89-98.
31. Mouledous L, Topham CM, Mazarguil H, Meunier JC. Direct identification of a peptide binding region in the opioid receptor-like 1 receptor by photoaffinity labeling with [Bpa(10),Tyr(14)]nociceptin. J. Biol. Chem. 2000; 275: 29268-29274.
32. Klco JM, Wiegand CB, Narzinski K, Baranski TJ. Essential role for the second extracellular loop in C5a receptor activation. Nat. Struct. Mol. Biol. 2005; 12: 320-326.
33. Ott TR, Troskie BE, Roeske RW, Illing N, Flanagan CA, Millar RP. Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist. Mol. Endocrinol. 2002; 16: 1079-1088.
34. Vertongen P, Solano RM, Juarranz MG, Perret J, Waelbroeck M, Robberecht P. Proline residue 280 in the second extracellular loop (EC2) of the VPAC2 receptor is essential for the receptor structure. Peptides 2001; 22: 1363-1370.
35. Baneres JL, Mesnier D, Martin A, Joubert L, Dumuis A, Bockaert J. Molecular characterization of a purified 5-HT4 receptor: a structural basis for drug efficacy. J. Biol. Chem. 2005; 280: 20253-20260.
36. Piotto M, Saudek V, Sklenar V. Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J. Biomol. NMR 1992; 2: 661-665.
37. Hwang TL, Shaka AJ. Water suppression that works. Excitation sculpting using arbitrary Wave-forms and Pulsed-field gradients. J. Magn. Reson., Ser. A 1995; 112: 275-279.
38. Shaka AJ, Lee CJ, Pines A. Iterative schemes for bilinear operators; application to spin decoupling. J. Magn. Reson. 1988; 77: 274-293.
39. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. NMRPIPE - a multidimensional spectral processing system based on Unix pipes. J. Biomol. NMR 1995; 6: 277-293.
40. Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T, Formankay JD, Kay LE. Backbone dynamics of the free and a phosphopeptide-complexed SRC homology-2 domain studied by N-15 NMR relaxation. Biochemistry 1994; 33: 5984-6003.
41. Ross JB, Szabo AG, Hogue CW. Enhancement of protein spectra with tryptophan analogs: fluorescence spectroscopy of protein-protein and protein-nucleic acid interactions. Methods Enzymol. 1997; 278: 151-190.
42. Adams PD, Chen Y, Ma K, Zagorski MG, Sonnichsen FD, McLaughlin ML, Barkley MD. Intramolecular quenching of tryptophan fluorescence by the peptide bond in cyclic hexapeptides. J. Am. Chem. Soc. 2002; 124: 9278-9286.
43. Guerrini R, Calo G, Rizzi A, Bianchi C, Lazarus LH, Salvadori S, Temussi PA, Regoli D. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide. J. Med. Chem. 1997; 40: 1789-1793.
44. Ryabov YE, Geraghty C, Varshney A, Fushman D. An efficient computational method for predicting rotational diffusion tensors of globular proteins using an ellipsoid representation. J. Am. Chem. Soc. 2006; 128: 15432-15444.
45. Wuthrich K. NMR of Proteins and Nucleic Acid used. John Wiley and Sons: New York, 1986.
46. Bockaert J, Pin JP. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999; 18: 1723-1729.
47. Klaudel L, Legowska A, Brzozowski K, Silberring J, Wojcik J. Solution conformational study of nociceptin and its 1-13 and 1-11 fragments using circular dichroism and two-dimensional NMR in conjunction with theoretical conformational analysis. J. Pept. Sci. 2004; 10: 678-690.
48. Orsini MJ, Nesmelova I, Young HC, Hargittai B, Beavers MP, Liu J, Connolly PJ, Middleton SA, Mayo KH. The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships. J. Biol. Chem. 2005; 280: 8134-8142.
49. Salvadori S, Picone D, Tancredi T, Guerrini R, Spadaccini R, Lazarus LH, Regoli D, Temussi PA. Solution conformation of nociceptin. Biochem. Biophys. Res. Commun. 1997; 233: 640-643.
50. Reinscheid RK, Ardati A, Monsma FJ, Civelli O. Structure-activity relationship studies on the novel neuropeptide orphanin FQ. J. Biol. Chem. 1996; 271: 14163-14168.
51. Dooley CT, Houghten RA. Orphanin FQ: receptor binding and analog structure activity relationships in rat brain. Life Sci. 1996; 59: PL23-PL29.